QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
NASDAQ:MDWD

MediWound - MDWD Stock Forecast, Price & News

$1.35
-0.09 (-6.25%)
(As of 12/6/2022 05:33 PM ET)
Add
Compare
Today's Range
$1.15
▼
$1.40
50-Day Range
$1.29
▼
$1.67
52-Week Range
$1.15
▼
$3.38
Volume
567,089 shs
Average Volume
123,226 shs
Market Capitalization
$54.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.88

MediWound MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
409.3% Upside
$6.88 Price Target
Short Interest
Healthy
0.23% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.65mentions of MediWound in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.47) to ($0.26) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

623rd out of 1,023 stocks

Medicinals & Botanicals Industry

5th out of 13 stocks

See Top Rated MarketRank™ Stocks Here
MDWD stock logo

About MediWound (NASDAQ:MDWD) Stock

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Receive MDWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.

MDWD Stock News Headlines

December 5, 2022 | finance.yahoo.com
MediWound Announces a 1-for-7 Reverse Share Split
December 2, 2022 | sg.finance.yahoo.com
MediWound Reports Third Quarter 2022 Financial Results and Provides Company Update
December 1, 2022 | americanbankingnews.com
MediWound (NASDAQ:MDWD) Stock Rating Upgraded by StockNews.com
November 9, 2022 | finance.yahoo.com
MediWound’s EscharEx Featured in Paper as a Potential Paradigm Shift Towards Non-Surgical Wound Bed Preparation in DFUs
November 3, 2022 | finance.yahoo.com
MediWound to Report Third Quarter 2022 Financial Results
October 25, 2022 | finance.yahoo.com
MediWound Announces Formation of Strategic Advisory Board
October 18, 2022 | globenewswire.com
MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022 - GlobeNewswire
October 18, 2022 | finance.yahoo.com
MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022
October 7, 2022 | globenewswire.com
MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings - GlobeNewswire
October 7, 2022 | finance.yahoo.com
MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings
September 24, 2022 | marketwatch.com
MediWound Shares Slide Premarket After Stock Offerings >MDWD - MarketWatch
September 23, 2022 | nasdaq.com
Health Care Sector Update for 09/22/2022: LLY, LUNA, ISRG, MDWD - Nasdaq
September 22, 2022 | seekingalpha.com
Spero, HeartBeam top healthcare gainers; MediWound, Vincerx lead losers' pack - Seeking Alpha
September 22, 2022 | benzinga.com
Why MediWound Is Trading Lower By Around 18%, Here Are 48 Stocks Moving In Thursday’s Mid-Day Session - A - Benzinga
September 22, 2022 | benzinga.com
Vericel to Present at the Ladenburg Thalmann Healthcare Conference - Vericel (NASDAQ:VCEL) - Benzinga
September 22, 2022 | benzinga.com
MediWound shares are trading lower after the company announced concurrent registered direct and private p - Benzinga
September 22, 2022 | globenewswire.com
MediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 Million - GlobeNewswire
September 22, 2022 | finance.yahoo.com
MediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 Million
September 20, 2022 | globenewswire.com
EMA Accepts MediWound's Application for Extended Indication - GlobeNewswire
September 20, 2022 | finance.yahoo.com
EMA Accepts MediWound’s Application for Extended Indication for NexoBrid to Treat Pediatric Patients with Severe Thermal Burns
September 12, 2022 | globenewswire.com
MediWound's NexoBrid® Highlighted in 45 Posters and - GlobeNewswire
September 12, 2022 | benzinga.com
MediWound (NASDAQ:MDWD) – MediWound's NexoBrid® Highlighted in 45 Posters and Presentations at the 19th E - Benzinga
September 12, 2022 | finance.yahoo.com
MediWound’s NexoBrid® Highlighted in 45 Posters and Presentations at the 19th European Burns Association Congress
September 8, 2022 | reuters.com
MDWD.P - Mediwound Ltd | Stock Price & Latest News | Reuters
September 8, 2022 | globenewswire.com
Enzymatic Debridement Market exhibiting a CAGR of 8.3 % and is expected to reach USD 680 Million by 2029 - GlobeNewswire
See More Headlines
Receive MDWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.

MDWD Company Calendar

Last Earnings
11/16/2021
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/16/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Medicinals & botanicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MDWD
CUSIP
N/A
CIK
1593984
Web
www.mediwound.com
Phone
972779714100
Fax
972-77-971-4111
Employees
77
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.88
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$5.50
Forecasted Upside/Downside
+409.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.53)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-13,550,000.00
Net Margins
-80.05%
Pretax Margin
-79.97%
Return on Equity
N/A
Return on Assets
-68.07%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.71
Quick Ratio
2.50

Sales & Book Value

Annual Sales
$23.76 million
Price / Sales
2.31
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.17) per share
Price / Book
-7.94

Miscellaneous

Outstanding Shares
40,735,000
Free Float
N/A
Market Cap
$54.99 million
Optionable
Not Optionable
Beta
1.10

Key Executives

  • Prof. Lior Rosenberg M.D. (Age 76)
    Co-Founder & Medical Director
    Comp: $398k
  • Mr. Boaz Gur-Lavie CPA (Age 48)
    M.B.A., Chief Financial Officer
    Comp: $309k
  • Mr. Yaron Meyer Adv. (Age 43)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $240k
  • Dr. Ety Klinger (Age 60)
    Chief R&D Officer
    Comp: $344k
  • Mr. Ofer Gonen B.Sc. (Age 49)
    Chief Exec. Officer
  • Mr. Tzvi Palash B.Sc. (Age 65)
    M.Sc., Chief Operating Officer
  • Mr. Stephen T. Wills CPA (Age 65)
    CPA, MST, Exec. Director
  • Dr. Robert J. Snyder CWS
    D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













MDWD Stock - Frequently Asked Questions

Should I buy or sell MediWound stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDWD shares.
View MDWD analyst ratings or view top-rated stocks.

What is MediWound's stock price forecast for 2023?

4 Wall Street analysts have issued 12-month price targets for MediWound's stock. Their MDWD share price forecasts range from $5.50 to $8.00. On average, they anticipate the company's share price to reach $6.88 in the next twelve months. This suggests a possible upside of 377.4% from the stock's current price.
View analysts price targets for MDWD or view top-rated stocks among Wall Street analysts.

How have MDWD shares performed in 2022?

MediWound's stock was trading at $2.36 on January 1st, 2022. Since then, MDWD stock has decreased by 39.0% and is now trading at $1.44.
View the best growth stocks for 2022 here.

Are investors shorting MediWound?

MediWound saw a increase in short interest in November. As of November 15th, there was short interest totaling 94,900 shares, an increase of 101.5% from the October 31st total of 47,100 shares. Based on an average trading volume of 137,200 shares, the days-to-cover ratio is currently 0.7 days.
View MediWound's Short Interest.

When is MediWound's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our MDWD earnings forecast.

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) released its quarterly earnings results on Tuesday, November, 16th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.01. The biopharmaceutical company earned $6.37 million during the quarter, compared to analyst estimates of $5.60 million. During the same quarter in the previous year, the firm posted ($0.07) earnings per share.

What other stocks do shareholders of MediWound own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).

What is MediWound's stock symbol?

MediWound trades on the NASDAQ under the ticker symbol "MDWD."

Who are MediWound's major shareholders?

MediWound's stock is owned by a number of retail and institutional investors. Top institutional investors include Armistice Capital LLC (5.78%), Altium Capital Management LP (3.85%), Sargent Investment Group LLC (1.70%), Renaissance Technologies LLC (1.29%), Essex Investment Management Co. LLC (0.71%) and Meitav Dash Investments Ltd. (0.83%).

How do I buy shares of MediWound?

Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MediWound's stock price today?

One share of MDWD stock can currently be purchased for approximately $1.44.

How much money does MediWound make?

MediWound (NASDAQ:MDWD) has a market capitalization of $58.67 million and generates $23.76 million in revenue each year. The biopharmaceutical company earns $-13,550,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis.

How can I contact MediWound?

MediWound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The official website for the company is www.mediwound.com. The biopharmaceutical company can be reached via phone at 972779714100, via email at afields@lhai.com, or via fax at 972-77-971-4111.

This page (NASDAQ:MDWD) was last updated on 12/6/2022 by MarketBeat.com Staff